Serum Anti-60S Ribosomal Protein L29 Antibody as a Novel Prognostic Marker for Unresectable Pancreatic Cancer

Abstract

Background/Aims: Recently, we found the presence of anti-60S ribosomal protein L29 antibody (anti-RPL29) in human sera, inhibiting the proliferation of pancreatic cancer cells in vitro. We aimed to estimate the association of serum anti-RPL29 levels with clinical features in patients affected with unresectable pancreatic cancer. Methods: We retrospectively reviewed 105 patients with unresectable pancreatic cancer. Serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay. The cut-off was represented by the 95th percentile in 62 healthy volunteers. Results: Median survival time (MST) was 11.1 months in 49 patients showing serum anti-RPL29 level >cut-off and 7.4 months in 56 patients showing serum anti-RPL29 level ≤cut-off. In locally advanced disease, MST was 17.9 months in 22 patients showing serum anti-RPL29 level >cut-off and 10.0 months in 19 patients showing serum anti-RPL29 level ≤cut-off. In metastatic disease, MST was 8.7 months in 27 patients showing serum anti-RPL29 level >cut-off and 5.9 months in 37 patients showing serum anti-RPL29 level ≤cut-off. In the multivariate Cox proportional hazard model, serum anti-RPL29 level >cut-off, abdominal or back pain, performance status, and metastatic disease were identified as independent prognostic factors. Conclusion: Serum anti-RPL29 levels may be a novel candidate for a prognostic marker for unresectable pancreatic cancer.

A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection

“…Based upon title/abstract reading 1341 articles were not relevant to the topic leading to the full text screening of 41 articles. Ten of these were excluded due to the following reasons (see also Supplementary File S1 ): three studies evaluated markers other than autoantibodies or diagnostic ones [ 10 – 12 ], two studies lacked cancer free controls [ 13 , 14 ], we were unable to calculate sensitivity and specificity in four studies [ 15 – 18 ] and one study did not provide the number of included controls [ 19 ] In the end, with four articles additionally identified through cross-referencing [ 20 – 23 ], 31 articles were included in our review [ 20 – 50 ].…”

N-Myristoylation by NMT1 Is POTEE-Dependent to Stimulate Liver Tumorigenesis via Differentially Regulating Ubiquitination of Targets

“…Moreover, Zhao, et al., uncovered that AHSG is up-regulated in esophageal squamous cell carcinoma, and might also act as a pro-tumorigenic protein ( 37 ). By contrast, lower expression of RPL29, the one belongs to the NDP, is predicted to have a poorer outcome of unresectable pancreatic cancer ( 38 ), providing further evidence that RPL29 might be anti-tumorigenic. In liver cancer cells, we have revealed that NUPs are more likely to be predominantly expressed than NDPs, because NUPs are less ubiquitinated than regulated by NMT1.…”

“The transcriptome-wide association search for genes and genetic variants which associate with BMI and gestational weight gain in women with type 1 diabetes”

“…We also found a variant correlating with GWG in RPL29P25 gene. The presence of anti-60S ribosomal protein L29 (RPL29) antibody in human serum was shown to inhibit the proliferation of pancreatic cancer cells in various cancers and it is believed to be a novel candidate for a prognostic marker for unresectable pancreatic cancer (Muro, Miyake, Kato, Tsutsumi, & Yamamoto, 2015). The knockdown of RPL29 leads to suppression of cell proliferation, induces cell arrest (at G0/G1phase), enhances cell apoptosis and decreases intracellular ROS generation (C. Li, Ge, Yin, Luo, & Chen, 2012).…”